Compare Stocks

→ Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$5.01 -0.6%	$5.58	$2.68 ▼ $8.22	$157.82M	3.99	296,992 shs	233,781 shs
PHIO Phio Pharmaceuticals	$0.72 +7.8%	$0.80	$0.50 ▼ $6.85	$3.32M	1.44	367,142 shs	55,928 shs
PXYN Praxsyn		$0.00	$0.00 ▼ $0.01	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	$0.10	$0.23	$0.25 ▼ $4.69	$351K	N/A	1.59 million shs	95,212 shs
XBIO Xenetic Biosciences	$3.77 -2.1%	$4.08	$2.55 ▼ $5.97	$5.81M	2.6	5,860 shs	1,003 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+4.56%	-9.19%	-23.98%	+22.93%	+28.24%
PHIO Phio Pharmaceuticals	-4.25%	+4.60%	-11.71%	+11.83%	-79.97%
PXYN Praxsyn	0.00%	0.00%	0.00%	0.00%	0.00%
TRPX Therapix Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
XBIO Xenetic Biosciences	0.00%	-0.26%	-2.53%	+16.67%	-12.50%

World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	0.8523 of 5 stars	3.5	0.0	0.0	0.0	1.6	0.8	0.6
PHIO Phio Pharmaceuticals	2.7757 of 5 stars	3.5	5.0	0.0	0.0	0.9	2.5	0.6
PXYN Praxsyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$24.00	379.04% Upside
PHIO Phio Pharmaceuticals	3.00	Buy	$4.00	453.02% Upside
PXYN Praxsyn	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest PHIO, XBIO, CAPR, PXYN, and TRPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/1/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
2/6/2024	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$25.18M	6.27	N/A	N/A	$0.73 per share	6.86
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$2.06 per share	N/A
PXYN Praxsyn	N/A	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	$2.54M	2.29	N/A	N/A	$6.36 per share	0.59

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$0.87	N/A	41.75	N/A	-88.52%	-299.67%	-45.54%	5/9/2024 (Estimated)
PHIO Phio Pharmaceuticals	-$10.83M	-$5.93	N/A	∞	N/A	N/A	-134.66%	-105.86%	5/9/2024 (Estimated)
PXYN Praxsyn	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	-$4.79M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	-$4.14M	-$2.75	N/A	N/A	N/A	-162.84%	-36.43%	-33.74%	5/9/2024 (Estimated)

Latest PHIO, XBIO, CAPR, PXYN, and TRPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	XBIO Xenetic Biosciences	-$0.87	-$0.77	+$0.10	-$0.77	$0.68 million	$0.67 million
2/29/2024	Q4 2023	CAPR Capricor Therapeutics	-$0.23	-$0.02	+$0.21	-$0.02	$5.80 million	$12.09 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PXYN Praxsyn	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	1.63	1.63
PHIO Phio Pharmaceuticals	N/A	5.70	5.71
PXYN Praxsyn	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	11.84	11.84

Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
PHIO Phio Pharmaceuticals	57.31%
PXYN Praxsyn	N/A
TRPX Therapix Biosciences	14.32%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	12.00%
PHIO Phio Pharmaceuticals	0.77%
PXYN Praxsyn	N/A
TRPX Therapix Biosciences	N/A
XBIO Xenetic Biosciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	31.50 million	27.72 million	Optionable
PHIO Phio Pharmaceuticals	9	4.59 million	4.56 million	Not Optionable
PXYN Praxsyn	66	N/A	N/A	Not Optionable
TRPX Therapix Biosciences	9	3.51 million	N/A	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.40 million	Not Optionable

PHIO, XBIO, CAPR, PXYN, and TRPX Headlines

Source	Headline
	Xenetic Biosciences Inc (XBIO) investing.com - April 10 at 3:28 PM
	Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 24 at 5:09 PM
	Xenetic Dips on Full-Year Results baystreet.ca - March 22 at 7:33 PM
	Xenetic Biosciences reports FY results msn.com - March 22 at 8:51 AM
	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results accesswire.com - March 22 at 8:00 AM
	Xenetic to advance DNase programme with UVA partnership msn.com - January 18 at 1:37 PM
	Xenetic Biosciences Inc XBIO morningstar.com - January 4 at 5:10 PM
	Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast benzinga.com - December 11 at 9:01 AM
	Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation finance.yahoo.com - November 30 at 10:39 AM
	Xenetic Biosciences: Q3 Earnings Insights benzinga.com - November 10 at 3:38 PM
	MediciNova: Q3 Earnings Snapshot washingtonpost.com - November 10 at 10:37 AM
	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference finance.yahoo.com - October 11 at 9:30 AM
	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? msn.com - July 13 at 1:44 PM
	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 5:06 PM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison \| Morningstar morningstar.com - May 5 at 10:21 AM
	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development finance.yahoo.com - May 4 at 10:02 AM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison finance.yahoo.com - May 3 at 10:26 AM
	HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation msn.com - April 12 at 10:37 PM
	Xenetic Biosciences forms research collaboration with TSRI pharmaceutical-technology.com - April 12 at 12:36 PM
	Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO) markets.businessinsider.com - April 12 at 2:30 AM
	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform finance.yahoo.com - April 11 at 8:43 AM
	JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finanznachrichten.de - March 16 at 12:09 PM
	JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finance.yahoo.com - March 16 at 12:09 PM
	XBIO Xenetic Biosciences, Inc. seekingalpha.com - February 23 at 11:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Capricor Therapeutics

NASDAQ:CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Phio Pharmaceuticals

NASDAQ:PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Praxsyn

OTCMKTS:PXYN

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.

Therapix Biosciences

NASDAQ:TRPX

Xenetic Biosciences

NASDAQ:XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial